MYGN

Business Context and Reporting Period

Company: Myriad Genetics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2005
Business Overview: Myriad is a biotechnology company focused on predictive medicine (genetic testing for disease risk) and therapeutic drug development. The company operates three segments: Research, Predictive Medicine, and Drug Development. As of the reporting date, the company has not yet attained profitability and maintains an accumulated deficit.

Key Financial Metrics

Segment Performance (Q3 2005):

• Predictive Medicine: Revenue of $21.5 million; Operating Gain of $6.7 million.
• Research: Revenue of $3.6 million; Operating Loss of $(2.5) million.
• Drug Development: No revenue; Operating Loss of $(14.3) million.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 50% year-over-year, driven by a 49% increase in Predictive Medicine revenue ($21.5M vs $14.4M) and a 57% increase in Research revenue ($3.6M vs $2.3M).
• Profitability: Net loss improved by approximately 8% to $9.2 million, despite a 41% increase in R&D expenses.
• Expense Increases:
  • R&D Expenses: Rose to $18.5 million (from $13.1 million) due to expanded clinical trials for Flurizan (Alzheimer's and prostate cancer) and Phase 1 trials for cancer compounds.
  • SG&A Expenses: Increased 9% to $10.9 million to support business growth.
• Liquidity: Cash and cash equivalents decreased by $10.8 million ($10.8M net decrease) primarily due to operating expenditures and capital investments. Total liquid assets (cash + marketable securities) stood at $103.0 million.
• Accounting Change: The company adopted FASB Statement No. 123R (Share-Based Payment) effective July 1, 2005, resulting in a share-based compensation expense of $239,000 for the quarter.

Guidance, Outlook, and Risks

Management Commentary & Outlook:
Management expects to incur losses for at least the next several years due to the expansion of drug discovery, clinical trials, and facility expansion. The company believes its existing capital resources are sufficient to maintain operations for at least the next two years. However, future capital requirements depend on clinical trial results and regulatory approvals.

Key Clinical Developments:

• Flurizan (Alzheimer's): Phase 3 study initiated for mild Alzheimer's; Phase 2 follow-on study ongoing. Phase 2 results showed 34-45% slowing in decline (not statistically significant but clinically relevant).
• Flurizan (Prostate Cancer): Phase 2b trial ongoing for pre-metastatic prostate cancer.
• MPC-6827 & MPC-2130: Phase 1 trials ongoing for solid tumors, brain metastases, and blood cancers.
• Preclinical Pipeline: Candidates for AIDS (MPI-49839), thrombosis (MPC-0920), and emesis (MPC-4505) are in late-stage preclinical development.

Risks and Contingencies:

• Clinical Trial Risk: No assurance that clinical trials will result in marketable products or meet timelines.
• Regulatory Risk: Dependence on FDA approval for drug candidates.
• Capital Requirements: Potential need to raise additional financing if capital resources are consumed faster than anticipated.
• Revenue Volatility: Predictive medicine revenues may fluctuate due to seasonality and market acceptance.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $103 million in liquid assets against the projected burn rate for ongoing Phase 3 and Phase 2b trials.
• Flurizan Phase 3 Design: Review the specific endpoints and enrollment progress of the 800-patient-per-arm Phase 3 Alzheimer's study.
• Revenue Recognition: Confirm the proportionality of research revenue recognition under the cost-to-cost method for collaboration agreements.
• Share-Based Compensation: Monitor the impact of the new FASB 123R adoption on future net loss, noting $5.2 million of unrecognized compensation cost remaining.
• Deferred Revenue: Analyze the $2.7 million increase in deferred revenue to understand the timing of future research revenue recognition.